Industry Newsbiopharmaimmunologyabbviedividend
AbbVie Reports Surging Drug Sales And Upgrades
6.0
AbbVie Inc. received an analyst upgrade on Dec. 10 when HSBC raised its price target from $225 to $265 and upgraded the stock to Buy, while Piper Sandler had earlier reaffirmed a $289 target. In Q3 2025 AbbVie's immunology drugs posted strong growth—Skyrizi $4.7B (46.8%), Rinvoq $2.18B (35.3%), Humira $993M (55.4%)—and the board raised the quarterly dividend to $1.73.
Key Points
- 1Announces analyst upgrade and higher price targets alongside robust Q3 immunology drug sales figures.
- 2Demonstrates portfolio strength as Skyrizi and Rinvoq drive multi-billion dollar revenue growth and future guidance.
- 3Impacts investors through a dividend increase and ambitious 2027 revenue targets that affect long-term valuation.
Scoring Rationale
Solid company results and analyst upgrades increase relevance; limited novelty and narrow pharma focus constrain broader impact.
Sources
Public references used for this report.
Practice with real Health & Insurance data
90 SQL & Python problems · 15 industry datasets
Used by DS/ML engineers at top companies
250 free problems · No credit card
See all Health & Insurance problems
